NEC Corp. subsidiary NEC Oncoimmunity AS recently received $4.8 million from the Coalition for Epidemic Preparedness Innovations to fund the development of vaccines for SARS-CoV-2 variants and other betacoronaviruses.
In the summer of 2020, when Veru Inc. began researching sabizabulin for treating COVID-19 patients, the company’s CEO was cautioned that the virus could be gone by the time a therapy could be developed. Nearly two years later, Veru still has the compound in development and just reported phase III data that could propel it toward an emergency use authorization.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biogen, Deinove, Gilead, Glaxosmithkline, Merck, Neurosigma, Novavax, Serum Institute.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biontech, Beigene, Biocytogen, BMS, Boundless, Evotec, Indivior, Olix.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adverum, Henlius, Ilias, Minerva, Regeneron, Sanofi, Triastek.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abionyx, Akston, Annexon, Aptinyx, Ardelyx, Erytech, Meji, Pathalys, Talaris, Tonix, Vyne.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Akebia, Aosaikang, Aspect, Astrazeneca, Emergex, Everest, Genmab, Halozyme, J&J, Medisix, Melinta, Moderna, Propella, Twist, Vaccitech.
When the U.S. FDA convened its Vaccines and Related Biological Products Advisory Committee (VRBPAC) April 6 to advise on a path forward to the next generation of COVID-19 vaccines and boosters, there was a lot of talk about all the unknowns.
RSS
